Arcturus Therapeutics (ARCT)ARK Investment Management added to its stake +158K shares

1.87M

Shares reported · +158K vs prior quarter

0.21%

Disclosed portfolio weight

$34.5M

Reported value

Holdings as of

Sep 30, 2025

Filed

Nov 12, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Nov 10, 2025Company filing · Form 8-K · ResultsReported its results

What came next

1. Dec 11, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“On December 11, 2025, Arcturus Therapeutics Holdings, Inc., a Delaware corporation (the “Company”) and Andy Sassine, Chief Financial Officer of the Company and a member of the Company’s Board of Directors (the “Board”), mutually agreed to end their employment relationship in an amicable manner effective December 31, 2025 (the “Separation Date”).”
2. Mar 3, 2026Company filing · Form 8-K · ResultsReported its results

How to read SEC Form 13F-HR

Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.

Full guide: What is an SEC Form 13F?

What else is on file for Arcturus Therapeutics

For Arcturus Therapeutics, OQRO holds 1 fund holdings report (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ARCT page.

How this filing works

• SEC Form 13F

Other disclosures at Arcturus Therapeutics

• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRMay 12, 2026
• SEC Form 13F-HRMay 7, 2026
• SEC Form 13F-HRFeb 11, 2026
• SEC Form 13F-HRFeb 11, 2026
• SEC Form 13F-HRNov 12, 2025

Everything OQRO holds on this company is on its ARCT page.